

Pharmacy Formulary Updates for March 2020

To offer a pharmacy benefit that is clinically appropriate and cost effective, we constantly review how we cover prescription medications. Periodic adjustments are made to meet these goals. With the exception of new-to-market medications, the changes below are reflected in our online Preferred Drug List.

The following is a list of drugs that changed formulary status in March 2020:

Drug Name	Tufts Health Public Plan Formulary
	Tufts Health Direct Formulary
Brukinsa	T2;PA
Givlaari	MB;PA
Reblozyl	MB;PA
Xenleta IV	MB
Xenleta	T3
Jatenzo	T3;PA;QL
Consensi	NC
Absorica LD	NC

Key:

- | | |
|--------------------------------|--|
| MB: Medical Benefit | QL: Quantity Limitation |
| NC: Not covered | SP: Specialty Pharmacy - provided through CVS/specialty |
| NTM: New-to-market | ST: Step Therapy |
| PA: Prior Authorization | |